Introduction: Nephroprotection in pediatric chronic kidney disease (CKD) has a major positive impact, both on residual renal function and on quality of life, by delaying the need for renal replacement therapy. To this day, nephroprotective drugs used in children are mainly limited to angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers; interestingly, as suggested by trials conducted in adults with CKD, sodium-glucose cotransporter 2 inhibitors (SGLT2i) might also be beneficial to pediatric patients. However, there are no validated data to this date documenting the effect of SGLT2i in pediatric patients with CKD. Methods: We present a retrospective single-center study reporting the use of dapagliflozin in pediatric patients with CKD, aiming to evaluate dapagliflozin safety profile as well as its potential for renal protection. Our study describes 7 patients with a mean age of 13.3 years (+/− 7.029) presenting with identified glomerulopathy, leading to CKD and already treated by ACE inhibitors. Patients received a daily dose of dapagliflozin of 5 or 10 mg. Results: Over a period of 15 months, all patients reported the medication as easy to use. After an initial dip, estimated glomerular filtration rate decline slope stabilized in all patients. Urinary albumin-over-creatinine ratio had a strong tendency to decrease after 6 months of treatment (p = 0.0684). Systolic blood pressure also had a tendency to decrease after 6 months of treatment (p = 0.1). No significant side effect was reported by the patients. Conclusion: The promising results presented in this study support the use of SGLT2i in pediatric patients with CKD, although larger, randomized controlled trials in pediatric patients are necessary to better characterize their effectiveness in this particular population.

1.
Becherucci
F
,
Roperto
RM
,
Materassi
M
,
Romagnani
P
.
Chronic kidney disease in children
.
Clin Kidney J
.
2016
;
9
(
4
):
583
91
.
2.
Harambat
J
,
Madden
I
,
Hogan
J
.
Épidémiologie de la maladie rénale chronique chez l’enfant [Epidemiology of pediatric chronic kidney disease]
.
Nephrol Ther
.
2021
;
17
(
6
):
476
84
.
3.
Harada
R
,
Hamasaki
Y
,
Okuda
Y
,
Hamada
R
,
Ishikura
K
.
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
.
Pediatr Nephrol
.
2022
;
37
(
6
):
1215
29
.
4.
The EMPA-KIDNEY Collaborative Group
,
Herrington
WG
,
Staplin
N
,
Wanner
C
,
Green
JB
,
Hauske
SJ
,
Emberson
JR
, et al
.
Empagliflozin in patients with chronic kidney disease
.
N Engl J Med
.
2023
;
388
(
2
):
117
27
.
5.
Heerspink
HJL
,
Stefánsson
BV
,
Correa-Rotter
R
,
Chertow
GM
,
Greene
T
,
Hou
FF
, et al
.
Dapagliflozin in patients with chronic kidney disease
.
N Engl J Med
.
2020
;
383
(
15
):
1436
46
.
6.
Perkovic
V
,
Jardine
MJ
,
Neal
B
,
Bompoint
S
,
Heerspink
HJL
,
Charytan
DM
, et al,
CREDENCE Trial Investigators
.
Canagliflozin and renal Outcomes in type 2 diabetes and Nephropathy
.
N Engl J Med
.
2019
;
380
(
24
):
2295
306
.
7.
Zannad
F
,
Ferreira
JP
,
Pocock
SJ
,
Zeller
C
,
Anker
SD
,
Butler
J
, et al
.
Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced
.
Circulation
.
2021
;
143
(
4
):
310
21
.
8.
Kula
AJ
.
Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
.
Pediatr Nephrol
.
2022
;
37
(
10
):
2267
76
.
9.
Tamborlane
WV
,
Laffel
LM
,
Shehadeh
N
,
Isganaitis
E
,
Van Name
M
,
Ratnayake
J
, et al
.
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
.
Lancet Diabetes Endocrinol
.
2022
;
10
(
5
):
341
50
.
10.
Pierce
CB
,
Muñoz
A
,
Ng
DK
,
Warady
BA
,
Furth
SL
,
Schwartz
GJ
.
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease
.
Kidney Int
.
2021
;
99
(
4
):
948
56
Epub 2020 Dec 8.
11.
Ng
DK
,
Pierce
CB
.
Kidney disease progression in children and young adults with pediatric CKD: epidemiologic perspectives and clinical applications
.
Semin Nephrol
.
2021
;
41
(
5
):
405
15
.
12.
Liu
J
,
Cui
J
,
Fang
X
,
Chen
J
,
Yan
W
,
Shen
Q
, et al
.
Efficacy and safety of dapagliflozin in children with inherited proteinuric kidney disease: a pilot study
.
Kidney Int Rep
.
2022
;
7
(
3
):
638
41
.
You do not currently have access to this content.